Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page
- Check7 days agoChange DetectedSite revision updated from version v3.4.3 to v3.5.0. No visible changes to the study details or page content.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.1%

- Check29 days agoNo Change Detected
- Check44 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2; no core content or functionality changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision: v3.4.1 was added, replacing Revision: v3.4.0, indicating a minor site version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedUI/metadata updates include adding a glossary display option, showing the label 'Last Update Submitted that Met QC Criteria', displaying 'No FEAR Act Data', and updating the revision to v3.4.0 (replacing v3.3.4) with minor capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check72 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no other study content or page functionality is affected.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.